myelodysplastic Syndormes

The FDA has granted Breakthrough Therapy Designation (BTD) to Venclexta (venetoclax) combined with azacitidine for the potential treatment of adult patients with myelodysplastic syndromes (MDS). Venclexta is being developed by AbbVie Inc (NYSE: ABBV) and Roche Holdings AG...

Barclays has raised the price target of Acceleron Pharma Inc (NASDAQ: XLRN) shares to $42 (18.5 percent upside) from $40, based on a recent data showing luspatercept's durability of response in MDS. Myelodysplastic Syndromes (MDS) is a condition where the bone marrow does not produce enough healthy...